Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience-Reference-Cited by-同舟云学术

Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real‐world experience

Published:2019-09-27 Issue:16 Volume:8 Page:6860-6870
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Jeon Young‐Woo¹²³^ORCID,Yoon Seugyun¹,Min Gi June¹,Park Sung‐Soo¹,Park Silvia¹,Yoon Jae‐Ho¹^ORCID,Lee Sung‐Eun¹^ORCID,Cho Byung‐Sik¹^ORCID,Eom Ki‐Seong¹,Kim Yoo‐Jin¹,Kim Hee‐Je¹,Lee Seok¹,Min Chang‐Ki¹,Lee Jong Wook¹^ORCID,Cho Seok‐Goo¹²³

Affiliation:

1. Division of Lymphoma‐Myeloma Catholic Hematology Hospital Seoul St. Mary's Hospital College of Medicine The Catholic University of Korea Seoul Korea

2. Institute for Translational Research and Molecular Imaging Catholic Institutes of Medical Science Seoul Korea

3. Laboratory of Immune Regulation Convergent Research Consortium for Immunologic Disease Seoul St. Mary's Hospital Seoul Korea

Funder

National Research Foundation of Korea(NRF) grant funded by the Korea government

The Korean Association of Internal Medicine grant

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2565

Reference26 articles.